Casdin Capital’s Kite Pharma, Inc. KITE Stock Holding History

Casdin Capital’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-106,000	Closed	-$19.1M	–	29
2017 Q3	$19.1M	Buy	106,000 +16,000	+18%	+$2.23M	5.38%	8
2017 Q2	$9.33M	Buy	90,000 +47,500	+112%	+$3.88M	3.45%	11
2017 Q1	$3.34M	Sell	42,500 -51,500	-55%	-$3.18M	1.97%	17
2016 Q4	$4.21M	Buy	94,000 +4,000	+4%	+$196K	3.48%	12
2016 Q3	$5.03M	Buy	90,000 +17,500	+24%	+$975K	4.07%	10
2016 Q2	$3.63M	Sell	72,500 -2,500	-3%	-$123K	3.61%	11
2016 Q1	$3.44M	Buy	75,000 +45,000	+150%	+$2.18M	3.95%	12
2015 Q4	$1.85M	Buy	+30,000	New	+$2.11M	1.63%	21

Casdin Capital's KITE Position: Q4 2017 in Review

Casdin Capital sold out of Kite Pharma, Inc. (KITE) in Q4 2017, closing a stake of 106,000 shares — an estimated $19.1M sold.

Casdin Capital first reported a position in KITE in Q4 2015 and held it in 8 quarters. The position peaked at $19.1M in Q3 2017. 0 funds tracked by Wall St. Rank hold KITE as of Q4 2017.

Casdin Capital reported no remaining Kite Pharma, Inc. position as of Q4 2017 after selling out during the quarter.
Casdin Capital sold 106,000 Kite Pharma, Inc. shares in Q4 2017, an estimated $19.1M.
Casdin Capital first reported a position in Kite Pharma, Inc. in Q4 2015 and held it in 8 quarters.
Casdin Capital's Kite Pharma, Inc. position peaked at $19.1M in Q3 2017.
0 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q4 2017.

Based on Casdin Capital's 13F filing for Q4 2017, filed 14 Feb 2018.